🧬 A recent study presented at #SPD2024 has shown promising results for Oleogel-S10, a treatment that could significantly reduce the burden of dressing changes in epidermolysis bullosa. https://lnkd.in/g9S_jvRw
About us
Dermatology Times is a leading news resource serving more than 16,000 dermatologists and other skin care professionals and focusing on the latest developments in dermatological practice, regulatory news, practice management, and new products. We strive to help practitioners understand and put into perspective developments that affect their profession and their business.
- Website
-
http://www.dermatologytimes.com
External link for Dermatology Times
- Industry
- Book and Periodical Publishing
- Company size
- 501-1,000 employees
- Headquarters
- Cranbury
- Type
- Public Company
Locations
-
Primary
Cranbury, US
Employees at Dermatology Times
Updates
-
A recent review found that patients with a history of alopecia areata (AA) or thyroid dysfunction may be at higher risk of developing AA after receiving the COVID-19 vaccine. Although these vaccines are generally safe, articles regarding their adverse effects have been published, including those on nausea, fever, muscle and joint pain, redness, and sweating. https://lnkd.in/gK9sF7HM
Alopecia Areata After COVID-19 Vaccines: Clinical Insights
dermatologytimes.com
-
📹 Join Alexa Hetzel, MS, PA-C; Andrew Mastro, MS, PA-C; T.J. Chao, MPAS, PA-C; and Terry Faleye, MPAS, PA-C, as they explore plaque psoriasis through patient case analyses and treatment paradigm evaluations, identifying potential areas for advancements in care. Watch here: https://ow.ly/1z2050SBphs
-
-
CUTISS AG recently announced new positive interim analysis data on the efficacy of its phase 2 trial evaluating denovoSkin in pediatric, adolescent, and adult patients in need of reconstructive skin surgery due to various conditions. "These results confirm Cutiss’s mission to provide access to denovoSkin beyond burns, improve patient outcomes, and change the status quo in skin surgery,” said Daniela Marino, CEO of Cutiss. https://lnkd.in/gTz4_8cd
New Positive Phase 2 Interim Analysis Confirms Efficacy of denovoSkin for Reconstructive Skin Surgery
dermatologytimes.com
-
📚 Results of a secondary study provided further evidence for the “rapid and sustained efficacy of dupilumab” for children aged 4 to 14 with moderate to severe #atopicdermatitis. https://lnkd.in/g_Jk3HKA
Continued Efficacy of Dupilumab for Children with AD
-
📰FROM OUR PUBLICATION: In a recent Dermatology Times custom video series, Alexandra Golant, MD, delved into the complexities of managing #atopicdermatitis with a particular focus on hand and foot involvement. https://lnkd.in/g7X2XJQD
Management of Atopic Dermatitis With Hand and Foot Involvement
dermatologytimes.com
-
👥 CONFERENCE HIGHLIGHTS: From insights in topical therapeutics to food triggers in eczema, view our recap of coverage from day 3 of #SPD2024. https://lnkd.in/gt46p8XA
Day 3 Recap: 2024 Society for Pediatric Dermatology Annual Meeting
-
🧬 A recent study, presented in a poster at #SPD2024, reported that tapinarof cream 1% (Vtama; Dermavant Sciences) is efficacious in #atopicdermatitis in pediatric patients with skin of color. https://lnkd.in/gVCXFw9Q
Tapinarof Cream 1% Demonstrates Efficacy in Treating Atopic Dermatitis in Young Patients with Skin of Color
-
📚 A poster from #SPD2924 reported that pediatric patients with congenital ichthyosis who were treated with TMB-001 0.05% exhibited notable improvements in skin symptoms and minimal systemic side effects. https://lnkd.in/g_J-JbZa
Topical Isotretinoin Shows Promise in Phase 3 ASCEND Trial for Congenital Ichthyosis